Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with hepatitis C virus genotype 2 or 3 infection: COMMAND GT2/3 studyG. J. Dore,E. Lawitz,C. Hezode,S. Shafran, A. Ramji,H. Tatum,G. Taliani,A. Tran,M. Brunetto,S. Zaltron,S. Strasser,N. Weis,W. Ghesquiere,S. Lee,D. Larrey,S. Pol,H. Harley, J. George,S. Fung,V. De Ledinghen,P. Hagens,D. Cohen,E. Cooney,S. Noviello,E. HughesJournal of Hepatology(2013)引用 41|浏览27暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络